Alveolar epithelial fluid transport can be simultaneously upregulated by both KGF and beta-agonist therapy

J Appl Physiol (1985). 1999 Nov;87(5):1852-60. doi: 10.1152/jappl.1999.87.5.1852.

Abstract

Although keratinocyte growth factor (KGF) protects against experimental acute lung injury, the mechanisms for the protective effect are incompletely understood. Therefore, the time-dependent effects of KGF on alveolar epithelial fluid transport were studied in rats 48-240 h after intratracheal administration of KGF (5 mg/kg). There was a marked proliferative response to KGF, measured both by in vivo bromodeoxyuridine staining and by staining with an antibody to a type II cell antigen. In controls, alveolar liquid clearance (ALC) was 23 +/- 3%/h. After KGF pretreatment, ALC was significantly increased to 30 +/- 2%/h at 48 h, to 39 +/- 2%/h at 72 h, and to 36 +/- 3%/h at 120 h compared with controls (P < 0.05). By 240 h, ALC had returned to near-control levels (26 +/- 2%/h). The increase in ALC was explained primarily by the proliferation of alveolar type II cells, since there was a good correlation between the number of alveolar type II cells and the increase in ALC (r = 0.92, P = 0.02). The fraction of ALC inhibited by amiloride was similar in control rats (33%) as in 72-h KGF-pretreated rats (38%), indicating that there was probably no major change in the apical pathways for Na uptake in the KGF-pretreated rats at this time point. However, more rapid ALC at 120 h, compared with 48 h after KGF treatment, may be explained by greater maturation of alpha-epithelial Na channel, since its expression was greater at 120 than at 48 h, whereas the number of type II cells was the same at these two time points. beta-Adrenergic stimulation with terbutaline 72 h after KGF pretreatment further increased ALC to 50 +/- 7%/h (P < 0.5). In summary, KGF induced a sustained increase over 120 h in the fluid transport capacity of the alveolar epithelium. This impressive upregulation in fluid transport was further enhanced with beta-adrenergic agonist therapy, thus providing evidence that two different treatments can simultaneously increase the fluid transport capacity of the alveolar epithelium.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adrenergic beta-Agonists / pharmacology*
  • Amiloride / pharmacology
  • Animals
  • Blotting, Northern
  • Body Fluids / physiology
  • Diuretics / pharmacology
  • Epithelial Cells / drug effects
  • Epithelial Cells / metabolism
  • Epithelium / drug effects
  • Epithelium / metabolism
  • Fibroblast Growth Factor 10
  • Fibroblast Growth Factor 7
  • Fibroblast Growth Factors*
  • Growth Substances / pharmacology*
  • Male
  • Permeability
  • Pulmonary Alveoli / drug effects
  • Pulmonary Alveoli / metabolism*
  • Rats
  • Rats, Sprague-Dawley
  • Sodium Channel Blockers
  • Sodium Channels / biosynthesis
  • Terbutaline / pharmacology
  • Time Factors
  • Up-Regulation / drug effects*

Substances

  • Adrenergic beta-Agonists
  • Diuretics
  • Fgf7 protein, rat
  • Fibroblast Growth Factor 10
  • Growth Substances
  • Sodium Channel Blockers
  • Sodium Channels
  • Fibroblast Growth Factor 7
  • Fibroblast Growth Factors
  • Amiloride
  • Terbutaline